TrialOrphanet journal of rare diseases2026

Sustained clinical benefit of idursulfase beta in mucopolysaccharidosis II: two-year experience from a phase 3 extension study including patients switched from idursulfase.

Minji Im et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.